Genome.One a partner in pioneering Digital Health CRC 

Genome.One has welcomed the announcement of the new Digital Health Cooperative Research Centre (CRC), which is set to develop and test digital health solutions to tackle some of the nation’s biggest health challenges.

Genome.One is one of the major industry partners in the collaboration that brings together 80 clinical, research, industry, government and educational organisations representing every segment of the health system, from patient to community, hospital to insurer, start-up to big government.

Assistant Minister for Science, Jobs and Innovation, Hon Senator Zed Seselija, launched the CRC in Sydney last week, saying it would improve the health and healthcare of all Australians. 

He said the Federal Government would invest $55 million in the Centre, and in total, the CRC would attract more than $200 million in cash and in-kind funding over seven years to pioneer digital health transformation.

“The CRC brings together industry and research partners across Australia’s health and wellness landscape in a collaborative approach to advancing health and medical technologies and pharmaceutical industries, ” Senator Seselija said.

Genome.One CEO Marcel Dinger (centre) joined collaborators at the Digital Health CRC launch.

Genomic health data integration

Genome.One CEO Associate Professor Marcel Dinger said the project provided an opportunity to further develop platforms that would see genomic data used to guide future healthcare decisions and interventions.

“The Digital Health CRC will enable the exploration of how we can integrate key health information, including genomics and phenomics data, into clinical decision making and population health interventions across our health services,” he said. 

He said Genome.One already was already working to integrate genome analytics, clinical data analytics and genetic pathology to derive clinically meaningful information from the genome. The CRC would help drive forward the company's vision of developing a platform to enable interpretation of the genome at patients’ point-of care to guide clinical decision making.

The Centre has already established an ambitious research and development agenda, with priorities including tackling adverse drug reactions, mining knowledge from health data and empowering consumers. 

Consortium chair Professor Christine Bennett AO said reducing adverse events was a key focus, as one in four Australians admitted to hospital would have an adverse event, and such events cost the health system an estimated $1.2 billion each year, of which 50% was avoidable.

 “Our CRC’s founding premise is that digital health solutions have the potential to improve people’s health and wellbeing, reduce waste in the health system and build businesses and jobs in the rapidly growing digital health sector” she said.

The Centre will operate through collaborative R&D programs involving: 40 commercial and government health, aged care and disability organisations; 24 established and start-up technology, advisory and investment companies including Genome.One; and 16 Australian universities.  The Centre has the support of both the Australian Digital Health Agency and the Medical Technologies and Pharmaceuticals industry growth centre (MTP Connect).

Find out more